NCT04326166
Unknown
Not Applicable
Multi-center, Open, Non-intervention and Observational Study to Evaluate the Efficacy and Safety of Suganon Tab. or Sugamet XR Tab. in Patients With Type 2 Diabetes
ConditionsDiabetes Mellitus, Type 2
Overview
- Phase
- Not Applicable
- Intervention
- Evogliptin
- Conditions
- Diabetes Mellitus, Type 2
- Sponsor
- Dong-A ST Co., Ltd.
- Enrollment
- 1971
- Locations
- 1
- Primary Endpoint
- Change in HbA1c
- Last Updated
- 5 years ago
Overview
Brief Summary
Multi-center, open, non-intervention and observational study to Evaluate the efficacy and safety of Suganon tab. or Sugamet XR tab. in patients with Type 2 diabetes
Investigators
Eligibility Criteria
Inclusion Criteria
- •The subject is aged ≥19 years
- •The subject has type 2 diabetes mellitus
Exclusion Criteria
- •The subject has a contraindication
Arms & Interventions
Group A
Patients who receive Double therapy or Insulin
Intervention: Evogliptin
Group B
Patients who receive DPP-4 inhibitor
Intervention: Evogliptin
Group C
Drug-naïve patients
Intervention: Metformin and Evogliptin
Outcomes
Primary Outcomes
Change in HbA1c
Time Frame: at 12 weeks
To assess change from baseline in HbA1c
Secondary Outcomes
- Change in HbA1c(at 24 weeks)
- Change in FPG(at 12 and 24 weeks)
- The percentage of patients with HbA1c <7.0% and <6.5%(at 12 and 24 weeks)
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine TumorsPancreatic Neuroendocrine TumorsNCT02282059Pfizer100
Completed
Not Applicable
Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real WorldGastrointestinal Stromal TumorsNCT05381753CStone Pharmaceuticals61
Completed
Phase 3
A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis ExacerbationsMyasthenia Gravis ExacerbationsNCT02413580Grifols Therapeutics LLC49
Completed
Not Applicable
An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line TherapyNon-Squamous Non-Small Cell Lung CancerNCT01664533Hoffmann-La Roche57
Completed
Not Applicable
Investigation of Preservative-Free Ophthalmic Solution in Ocular DrynessDry Eye SyndromesNCT05778942SIFI SpA35